OAC
EGRX

OMERS Administration Corp’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

OMERS Administration Corp’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,000
Closed -$322K – 209
2020
Q1 		$322K Buy
+7,000
New +$351K 0.01% 142

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OMERS Administration Corp's EGRX Position: Q2 2020 in Review

OMERS Administration Corp sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 7,000 shares — an estimated $322K sold.

OMERS Administration Corp first reported a position in EGRX in Q1 2020 and held it in 1 quarter. The position peaked at $322K in Q1 2020. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

  • OMERS Administration Corp reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
  • OMERS Administration Corp sold 7,000 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $322K.
  • OMERS Administration Corp first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and held it in 1 quarter.
  • OMERS Administration Corp's Eagle Pharmaceuticals, Inc. position peaked at $322K in Q1 2020.
  • 164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on OMERS Administration Corp's 13F filing for Q2 2020, filed 14 Aug 2020.